DK0944631T3 - Nye substituerede pyrazolderivater til behandling af hjertekredslöbssygdomme - Google Patents

Nye substituerede pyrazolderivater til behandling af hjertekredslöbssygdomme

Info

Publication number
DK0944631T3
DK0944631T3 DK97951204T DK97951204T DK0944631T3 DK 0944631 T3 DK0944631 T3 DK 0944631T3 DK 97951204 T DK97951204 T DK 97951204T DK 97951204 T DK97951204 T DK 97951204T DK 0944631 T3 DK0944631 T3 DK 0944631T3
Authority
DK
Denmark
Prior art keywords
treatment
cardiovascular disease
pyrazole derivatives
substituted pyrazole
new substituted
Prior art date
Application number
DK97951204T
Other languages
English (en)
Inventor
Alexander Straub
Chantal Robyr
Thomas Jaetsch
Achim Feurer
Raimund Kast
Johannes-Peter Stasch
Elisabeth Perzborn
Joachim Huetter
Klaus Dembowsky
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK0944631T3 publication Critical patent/DK0944631T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97951204T 1996-11-26 1997-11-14 Nye substituerede pyrazolderivater til behandling af hjertekredslöbssygdomme DK0944631T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19649460A DE19649460A1 (de) 1996-11-26 1996-11-26 Neue substituierte Pyrazolderivate

Publications (1)

Publication Number Publication Date
DK0944631T3 true DK0944631T3 (da) 2004-06-07

Family

ID=7813100

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97951204T DK0944631T3 (da) 1996-11-26 1997-11-14 Nye substituerede pyrazolderivater til behandling af hjertekredslöbssygdomme

Country Status (25)

Country Link
EP (1) EP0944631B1 (da)
JP (2) JP4422800B2 (da)
CN (1) CN1122032C (da)
AR (1) AR010310A1 (da)
AT (1) ATE259812T1 (da)
AU (1) AU729642B2 (da)
BR (1) BR9714363A (da)
CA (1) CA2272584C (da)
CZ (1) CZ185099A3 (da)
DE (2) DE19649460A1 (da)
DK (1) DK0944631T3 (da)
EE (1) EE9900211A (da)
ES (1) ES2214646T3 (da)
HU (1) HUP0000562A3 (da)
ID (1) ID21881A (da)
IL (1) IL129998A0 (da)
MX (1) MXPA99004826A (da)
NO (1) NO992400L (da)
NZ (1) NZ335890A (da)
PT (1) PT944631E (da)
SK (1) SK67699A3 (da)
TR (1) TR199901172T2 (da)
TW (1) TW403746B (da)
WO (1) WO1998023619A1 (da)
ZA (1) ZA9710573B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19827679A1 (de) * 1998-06-22 1999-12-23 Dresden Arzneimittel Adenosinrezeptoraffine, antikonvulsiv und antiallergisch/antiasthmatisch wirkende Pyrazolo[3,4-d]pyrimidine und Verfahren zu deren Herstellung
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19920352A1 (de) * 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10021069A1 (de) * 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
CA2429308C (en) 2000-11-22 2010-09-21 Bayer Aktiengesellschaft Novel lactam-substituted pyrazolopyridine derivatives
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) * 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ,インク. 化合物、組成物および方法
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007015034A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
US8759345B2 (en) 2008-04-28 2014-06-24 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
JP6005134B2 (ja) * 2011-04-21 2016-10-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH フルオロアルキル置換ピラゾロピリジンおよびその使用
US9150574B2 (en) 2011-09-14 2015-10-06 Proximagen Limited Enzyme inhibitor compounds
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20180169095A1 (en) 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
CN113750102A (zh) 2015-07-23 2021-12-07 拜耳制药股份公司 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途
JP2019502686A (ja) 2015-12-14 2019-01-31 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化管括約筋機能障害の治療へのsGC刺激薬の使用
WO2017121700A1 (de) * 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
WO2018069148A1 (de) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
JP7101688B2 (ja) 2016-10-11 2022-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト sGC刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
JP7090639B2 (ja) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
JP2021523201A (ja) 2018-05-15 2021-09-02 バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft 神経線維感作に関連する疾患を治療するための1,3−チアゾール−2−イル置換ベンズアミド
JP7542518B2 (ja) 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア(mitochonrial)障害の処置のためのsGC刺激剤の使用
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0615542B2 (ja) * 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
EP0641564A4 (en) * 1992-05-21 1995-05-03 Yoshitomi Pharmaceutical OPTICALLY ACTIVE CONDENSED PYRAZOLIC COMPOUNDS FOR USE IN THE TREATMENT OF THROMBOZYTOPENIA AND ERYTHROPENIA.
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
CN1039536C (zh) * 1994-02-28 1998-08-19 永信药品工业股份有限公司 1,3取代缩合吡唑类化合物及其应用和制备方法

Also Published As

Publication number Publication date
NO992400D0 (no) 1999-05-19
AU729642B2 (en) 2001-02-08
BR9714363A (pt) 2000-03-21
ES2214646T3 (es) 2004-09-16
MXPA99004826A (es) 2008-02-19
HUP0000562A2 (hu) 2000-10-28
NO992400L (no) 1999-05-19
DE19649460A1 (de) 1998-05-28
ZA9710573B (en) 1998-06-10
SK67699A3 (en) 2000-02-14
CZ185099A3 (cs) 1999-08-11
ATE259812T1 (de) 2004-03-15
PT944631E (pt) 2004-06-30
NZ335890A (en) 2001-02-23
TR199901172T2 (xx) 1999-08-23
IL129998A0 (en) 2000-02-29
JP2001505567A (ja) 2001-04-24
AU5482398A (en) 1998-06-22
JP4422800B2 (ja) 2010-02-24
HUP0000562A3 (en) 2001-12-28
EP0944631B1 (de) 2004-02-18
DE59711321D1 (de) 2004-03-25
ID21881A (id) 1999-08-05
CA2272584C (en) 2007-10-16
CN1238773A (zh) 1999-12-15
CN1122032C (zh) 2003-09-24
JP2010013475A (ja) 2010-01-21
WO1998023619A1 (de) 1998-06-04
TW403746B (en) 2000-09-01
HK1023119A1 (en) 2000-09-01
EE9900211A (et) 1999-12-15
EP0944631A1 (de) 1999-09-29
CA2272584A1 (en) 1998-06-04
AR010310A1 (es) 2000-06-07

Similar Documents

Publication Publication Date Title
NO992400D0 (no) Nye substituerte pyrazolderivater
DK0773940T4 (da) Fremgangsmåde til syntese af substituerede sulfoxider
DK1028954T3 (da) Substituerede imidazoler egnede til behandling af inflammatoriske sygdomme
NO995113L (no) Substituerte benzopyranderivater for behandling av inflammasjon
DK0769947T3 (da) Indolinonforbindelser til behandling af sygdom
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
NO20000226D0 (no) Nye spiroazabicykliske heterocykliske forbindelser
NO983356D0 (no) Nye 19-nor-pregnenderivater
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
NO974605D0 (no) Nye heterosykliske forbindelser
DK0966444T3 (da) Fremgangsmåde til fremstilling af pyrazolderivater
DK0768310T3 (da) Fremgangsmåde til fremstilling af imidazo-benzodiazepin-derivater
DK0983275T3 (da) Nye triptolidderivater, der er nyttige til behandling af autoimmune sygdomme
DK0877738T3 (da) Fremgangsmåde til fremstilling af phenylimidazolidinderivater
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
DK0975594T3 (da) Fremgangsmåde til fremstilling af indolderivater
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
DK0864564T3 (da) Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater
DK0842930T3 (da) Fremgangsmåde til syntese af benzothiophener
DK0855379T3 (da) Fremgangsmåde til fremstilling af benzophenonderivater
DK0810216T3 (da) Derivater af 10,11-dihydro-10-oxo-5H-dibenz/b/,f/azepin-5-carboxamid
NO993549L (no) Imino-aza-antracyklinonderivater til behandling av amyloidosis
NO981216D0 (no) Nye heterosykliske forbindelser
DK0787729T3 (da) Fremgangsmåde til fremstilling af imidazodiazepinderivater
DK0964681T3 (da) Antikonvulsive derivater til behandling af psoriasis